Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1411)	4/10/2002 12:48:09 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 1826

MGI Pharma Says Study Shows Irofulven Effective DOW JONES NEWSWIRES MINNEAPOLIS -- MGI Pharma Inc. (MOGN) said preclinical and clinical studies show effective anti-tumor activity of irofulven in combination with cancer therapies. In a press release Wednesday, the company said it plans to develop irofulven for use with a variety of cancers, as well as further combination trials with other therapies. Irofulven is MGI's anti-cancer compound that displays anti-tumor activity and retains cytotoxic activity, or cell death, in tumors with different types of drug resistance mechanisms. According to MGI, irofulven has displayed activity as a single agent in clinical trials, and several preclinical studies have demonstrated enhanced anti-tumor activity in various cell lines and xenografts when irofulven has been used in combination with other anti-cancer agents. MGI is currently conducting a Phase III trial of irofulven in advanced-stage, gemcitabine-refractory pancreatic cancer patients, for which it received fast track designation from the Food and Drug Administration. Irofulven is also being studied for use in combination with Camptosar, Gemzar, Taxotere, and cisplatin. Side effects from irofulven are similar to marketed chemotherapies and include bone marrow suppression, nausea, vomiting, fatigue, and visual disturbances.